BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


Ti-Hao Wang

Session 7 – Sharing Biotech Successes-Taiwan BIO Awardee Showcase

Date:27 July (Thursday)
Time:10:40 – 12:10 (GMT+8)

Ti-Hao Wang

Deputy General Manager of Technology
Research & Development Ever Fortune.AI Co., Lt

Ti-Hao Wang earned his medical doctor degree from National Taiwan University. He completed his radiation oncology residency training in Taipei Veterans General Hospital.

He is on a mission to bridge state-of-the-art informatic technology to medicine. Trained as a radiation oncologist, he has a solid background in cancer care. What makes him unique is during his clinical career, he developed several integrated workflow systems to help clinician increase efficiency. He also has experience in deep learning, computer vision, and natural language processing. Currently, he works at China Medical University Hospital as a board-certified attending physician and is also the R&D director of Everfortune.AI, Ltd.

Company Profile

Everfortune.AI, established by accomplished physicians, specializes in building a unique healthcare data lake. Our mission is to offer cloud-based services across neurology, cardiology, oncology, and nephrology sectors, intending to provide comprehensive solutions for the healthcare and medical device industry.

We boast of 6 U.S. FDA and 11 Taiwan FDA approvals, alongside 22 globally recognized patents across artificial intelligence, medical devices, and platform technologies. These proven records, earned over just five years, position us as a digital healthcare industry leader.

Our B2B-focused model facilitates strategic partnerships with global frontrunners in the healthcare sector, extending our customer network and footprint across Taiwan, the United States, France, Singapore, and Hong Kong. Everfortune.AI is committed to healthcare AI R&D investments, fostering rapid market penetration, and maintaining industry leadership.

Looking forward, we aim to continue expanding our digital healthcare services, underlining our commitment to sustainable growth and global health quality enhancement through innovative technology.